WO1999013891A1 - Preparation therapeutique renfermant du cartilage de requin - Google Patents

Preparation therapeutique renfermant du cartilage de requin Download PDF

Info

Publication number
WO1999013891A1
WO1999013891A1 PCT/AU1998/000760 AU9800760W WO9913891A1 WO 1999013891 A1 WO1999013891 A1 WO 1999013891A1 AU 9800760 W AU9800760 W AU 9800760W WO 9913891 A1 WO9913891 A1 WO 9913891A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
composition
shark cartilage
composition according
emu
Prior art date
Application number
PCT/AU1998/000760
Other languages
English (en)
Inventor
John Alfred Drinkwater
Raymond John Attard
Philip Andre Delacretaz
Original Assignee
Micronized Foods Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micronized Foods Pty. Ltd. filed Critical Micronized Foods Pty. Ltd.
Priority to AU90553/98A priority Critical patent/AU9055398A/en
Publication of WO1999013891A1 publication Critical patent/WO1999013891A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs

Definitions

  • the present invention relates to a composition comprising shark cartilage and a natural oil, and to medical treatments using such a composition.
  • the invention relates to a composition comprising shark cartilage and emu oil, which is useful for the treatment of injuries or disorders to the epithelium, skin or joints.
  • the present invention relates to the use of the shark cartilage and emu oil composition in the treatment of burns, cancer, and inflammation, particularly in humans .
  • compositions or preparations based on natural substances are often popular with the general public, due to the perception that natural products are of superior quality or less likely to have contraindications compared to equivalent chemical products synthesised in a laboratory.
  • the high regard for natural substances for use in pharmaceutical and therapeutic compositions or preparations is reflected in the continuing popularity through the centuries of homoeopathic medicine and natural remedies such as those used in Asia and Eastern Europe .
  • shark's fin soup has been eaten for centuries because of its reputed therapeutic properties, and particularly for its reputed action as a cancer prophylactic.
  • numerous research papers have been published regarding the therapeutic effects of shark cartilage.
  • shark cartilage may stimulate the cellular and humoral components of the immune system. This makes shark cartilage effective against bacterial, viral and fungal infections, and consequently may provide support to the immune system against colds, influenza and other infections.
  • Shark cartilage has also been shown to contain powerful anti-inflammatory agents, and to provide wound healing. Consequently it is believed that shark cartilage may provide a source of relief from the effects of degenerative bone and joint disorders such as arthritis, rheumatoid arthritis, osteoarthritis and sports-related injuries.
  • Shark cartilage also contains an anti- angiogenesis factor, which inhibits the growth of new blood vessels. Accordingly, shark cartilage may be utilised as a cancer treatment by inhibiting the vascularisation of tumours .
  • One of the problems associated with the use of shark cartilage relates to the inability to deliver sufficient amounts of shark cartilage components to a patient to provide an effective dose.
  • the treatment disclosed in the preceding article does not lend itself to self-administration by the patient on a long-term basis, utilises a pharmaceutical formulation that is relatively expensive to prepare (due to the need for extraction at high temperature and under high pressure), and is limited to administration of relatively low quantities (between about 2Y2 and 20 grams) of active agent per month.
  • Other routes that have been used to deliver shark cartilage components include rectal and vaginal administration. While these routes allow greater volumes of shark cartilage to be delivered, the ability to deliver optimal quantities of shark cartilage, namely, 60 to 100 grams per day, is practically impossible via these routes. Furthermore, patients report discomfort and feelings of invasion, when shark cartilage is delivered vaginally or anally.
  • shark cartilage is known to have potential benefit as an anti-inflammatory agent, anti- angiogenesis agent and agent for the stimulation of the cellular and humoral components of the immune system, it has not hitherto been successfully or widely used for these applications because it has not been possible to achieve suitable levels of tissue penetration, particularly skin penetration.
  • Natural oils are particularly popular components for pharmaceutical and therapeutic compositions or preparations. These include a vast range of plant derived oils such as evening primrose, coconut, palm, guaiac wood, citrus, origanum, patchouly, rose, sweet birch, rose oil, tagetes, cloves and costus oils. Commonly used fish oils include cod liver oil and shark liver oil. In recent times animal oils have not generally been as popular as fish oils or plant oils for pharmaceutical and therapeutic compositions, particularly for oral administration, because they generally have high saturated fat levels and high cholesterol levels which are perceived by the general public as "unhealthy". However some animal oils such as goanna oil and emu oil appear to have avoided this label.
  • Emu oil is an opaque whitish solid of waxy texture derived from the flesh, particularly the fat, of emus, and has an excellent ability to penetrate skin.
  • Emu oil is predominantly lipid, mainly in the form of triacylglycerols, with free fatty acids as a minor component (up to about 10%) .
  • the majority of the fatty acids are monounsaturated (about 51-55%) or saturated fatty acids (about 37-38%) ; a minority are polyunsaturated fatty acids (about 7-12%) .
  • the cholesterol levels of such oils is about 200-300 micrograms/gram oil, which is lower than those of fish-derived oils.
  • emu oil is similar to that of many of the oils of plant origin such as evening primrose oil, coconut, palm, sunflower and canola.
  • oils of plant origin are already widely produced at relatively low cost and used in large volumes in foodstuffs and pharmaceutical or therapeutic compositions, there has not hitherto been a great incentive or need to include emu oil in these types of composition or preparations.
  • Emu oil available commercially is commonly sold as a liniment or emollient.
  • a pharmaceutical and/or therapeutic composition comprising natural substances and having exceptional skin penetrating and physiological response characteristics can be provided by the combination of shark cartilage and emu oil.
  • the composition can be formed into an easily applied, stable product with a shelf life of at least 12 months.
  • the present invention attempts to overcome or at least alleviate some of the problems associated with providing a composition comprising natural substances for use in treating one or more types of injuries or disorders, particularly, injuries or disorders of the epithelium, skin or joints.
  • the present invention provides a composition comprising shark cartilage, natural oil and a pharmaceutically acceptable carrier, wherein the composition is readily absorbed into animal tissue.
  • the natural oil is emu oil.
  • a method of treating an injury or disorder comprising the step of administering or applying to a patient in need thereof an effective amount of a composition comprising, shark cartilage and emu oil.
  • a method of preparing a composition for the treatment of an injury or disorder comprising the step of mixing shark cartilage and emu oil.
  • the emu oil and shark cartilage in combination exhibits superior tissue penetration and superior physiological response compared to the tissue penetration of shark cartilage (and perhaps also emu oil) alone. Without wishing to be bound by theory it is believed that emu oil may increase the tissue penetration and/or act as an adjuvant for the shark cartilage. Shark cartilage may also have a similar effect on the emu oil.
  • the emu oil for use in the composition of the present invention is prepared by a process which comprises a fat-reducing stage and an oil reduction stage. It is particularly preferred that there is no water contamination in the fat-reducing stage, and that the oil extraction is carried out at low temperature.
  • the shark cartilage for use in the composition of the present invention is prepared by a process which comprises a drying stage and a milling stage. It is particularly preferred that the drying and milling are carried out at low temperature.
  • the composition of the present invention comprises between 5 and 90 wt%, more preferably between 10 and 70 wt%, or even more preferably between 20 and 60 wt% shark cartilage. Most preferably 50% cartilage is used.
  • the composition of the present invention comprises between 0.1 and 50 wt%, more preferably between 1 and 30 wt%, or even more preferably between 3 and
  • the composition of the present invention comprises between 30 and 60 wt% shark cartilage in combination with between 3 and 8 wt% emu oil.
  • the shark cartilage and emu oil are mixed with one or more suitable, convenient or desirable components to form a suitable preparation or composition.
  • the components may for example be a suitable base, emollient, demulcent, emulsifier, preservative or other additive.
  • Suitable components may for example, be chosen from the group consisting of; hydrocarbons such as paraffin, petrolatum, white petrolatum, mineral oil, light mineral oil, and hydrophilic petrolatum; animal fats such as anhydrous lanolin and lanolin; demulcents such as gums, mucilages or starches, including gum arabic, acacia syrup, gum tragacanth, licorice root, agar, sodium alginate, methylcellulose, sodium carboxymethylcellulose, glycerin, propylene glycol, polyethylene glycols, and tetraglycine; vegetable oils such as olive oil, cottonseed oil, corn oil, almond oil, peanut oil, persic oil and cocoa butter; inorganic additives such as zinc oxide, zinc sulphate, aluminium silicate; and combinations thereof.
  • hydrocarbons such as paraffin, petrolatum, white petrolatum, mineral oil, light mineral oil, and hydrophilic petrolatum
  • animal fats such as anhydrous lanolin and
  • the shark cartilage and emu oil may be mixed with an existing pharmaceutical or therapeutic composition such as calamine lotion (essentially a pink insoluble powder of zinc oxide) or a common ointment base such as a combination of calamine (8 wt%) , zinc oxide (2 wt%) , 2 wt% glycerine in bentonite magma (native colloidal, hydrated aluminium silicate) or olive oil and rosewater, aloe vera, wattle oil, orange oil or other oil(s).
  • an existing pharmaceutical or therapeutic composition such as calamine lotion (essentially a pink insoluble powder of zinc oxide) or a common ointment base such as a combination of calamine (8 wt%) , zinc oxide (2 wt%) , 2 wt% glycerine in bentonite magma (native colloidal, hydrated aluminium silicate) or olive oil and rosewater, aloe vera, wattle oil, orange oil or other oil(s).
  • the composition can take any suitable form, such as ointments, pastes, lotions, creams, liniments and the like, including aqueous creams, lanolin based ointments and emulsions.
  • the method of application or administration of the preparation or composition is dependent on the dosage and concentration of the emu oil and shark cartilage in the composition, so that undesirable effects of the composition are taken into account. For example, it may be necessary to take into account any toxicity or hypersensitivity of the individual to shark cartilage or emu oil in certain concentrations and/or dosages.
  • the method of application and/or administration of the preparation or composition is determined so as to be efficient and efficacious without being harmful .
  • the preparation or composition of the present invention will be used for one or more of the following: as an anti-inflammatory agent such as for use in the treatment of skin, joint and muscular injuries such as sunburn and degenerative bone or joint disorders such as arthritis, rheumatoid arthritis and osteoarthritis;
  • an anti-inflammatory agent such as for use in the treatment of skin, joint and muscular injuries such as sunburn and degenerative bone or joint disorders such as arthritis, rheumatoid arthritis and osteoarthritis;
  • antibacterial, antiviral and/or antifungal agent such as for use in the treatment of immune system disorders and infections including colds and influenza;
  • an anti-angiogenesis agent for the treatment of disorders such as haemorrhoids or tumours or carcinomas .
  • the pharmaceutical and/or therapeutic composition of the present invention typically finds application in the treatment of open wounds, haemorrhoids, skin cancers, burns, joint and muscle inflammation and tumours.
  • a composition according to the present invention was prepared by the combination of shark cartilage (30 wt%) and emu oil (5 wt%) .
  • composition was applied to 20 human subjects suffering open anal wounds. All subjects reported that the composition reduced inflammation and redness associated with the wound and generally soothed the affected area. Stimulation of the healing process was also noted.
  • Example 1 The composition of Example 1 was applied to haemorrhoids of 3 human subjects. Both subjects reported rapid contraction and disappearance of the haemorrhoids.
  • Example 1 The composition of Example 1 was applied to several basal cell carcinomas of 4 human subjects. The redness and size of the carcinomas appeared to be reduced.
  • Example 1 The composition of Example 1 was applied to an ulcerated flesh wound of a subject which eventually healed.
  • the quality of the skin growth was of superior quality and appearance to a similar wound on the same subject which was left to heal without the application of the composition of the present invention.
  • Example 1 The composition of Example 1 was topically applied to 3 subjects by a professional masseur. The subjects reported reduced redness and inflammation in joints and injured muscles to which the composition was applied.
  • Example 1 The composition of Example 1 was topically applied to 6 subjects with severe sunburn. The subject reported that the soreness associated with the sunburn was gone within 30 minutes and the following day there was virtually no redness and inflammation. The subject did not peel.
  • a composition according to the present invention was prepared by the combination of shark cartilage (50 wt%) , emu oil (5 wt%) , food grade preservatives, food grade gel base, minor oils, alovera, wattle oil and orange oil. The components were mixed together at room temperature and no heat was supplied to the process .
  • composition was used successfully in the treatment of skin rashes on dogs and horses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à une composition renfermant du cartilage de requin et une essence naturelle, ainsi qu'à des traitements médicaux utilisant une telle composition. En particulier, l'invention concerne une composition renfermant du cartilage de requin et de l'essence d'ému, utilisée pour le traitement de blessures ou d'affections de l'épithélium, de la peau ou des articulations. Plus particulièrement, l'invention se rapporte à l'utilisation d'une composition à base de cartilage de requin et d'essence d'ému pour le traitement de brûlures, de cancers et d'inflammations, principalement chez l'être humain.
PCT/AU1998/000760 1997-09-16 1998-09-16 Preparation therapeutique renfermant du cartilage de requin WO1999013891A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU90553/98A AU9055398A (en) 1997-09-16 1998-09-16 Therapeutic preparation comprising shark cartilage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO9205A AUPO920597A0 (en) 1997-09-16 1997-09-16 Pharmaceutical and/or therapeutic composition or preparation comprising shark cartilage and emu oil
AUPO9205 1997-09-16

Publications (1)

Publication Number Publication Date
WO1999013891A1 true WO1999013891A1 (fr) 1999-03-25

Family

ID=3803490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1998/000760 WO1999013891A1 (fr) 1997-09-16 1998-09-16 Preparation therapeutique renfermant du cartilage de requin

Country Status (2)

Country Link
AU (1) AUPO920597A0 (fr)
WO (1) WO1999013891A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655260B2 (en) * 2003-08-05 2010-02-02 Thomsen Joern Oddershede Supplement preparation
WO2013163324A1 (fr) * 2012-04-26 2013-10-31 Balaguer Xavier Gras Méthode de traitement du prurit avec de l'extrait de cartilage

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444752A (en) * 1982-09-13 1984-04-24 Lescarden Ltd. Method for treating progressive systemic sclerosis
WO1996023512A1 (fr) * 1995-02-03 1996-08-08 Les Laboratoires Aeterna Inc. Extraits de cartilage de requin, procede de preparation et utilisations de ces extraits

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444752A (en) * 1982-09-13 1984-04-24 Lescarden Ltd. Method for treating progressive systemic sclerosis
WO1996023512A1 (fr) * 1995-02-03 1996-08-08 Les Laboratoires Aeterna Inc. Extraits de cartilage de requin, procede de preparation et utilisations de ces extraits

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FED. PROC., Volume 45, No. 4, 1986, C.A. LUER, "Inhibitors of Angiogenesis from Shark Cartilage", page 949, Abstract 4624. *
PATENT ABSTRACTS OF JAPAN; & JP 07308169 A (HAPUTO INTERNATL:KK, PETSUKAA:KK) 28 November 1995. *
SCIENCE, Volume 221, No. 4616, 16 September 1983, Lancaster, PA, US, ANNE LEE et al., "Shark Cartilage Contains Inhibitors of Tumor Angiogenesis", pages 1185-1187. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655260B2 (en) * 2003-08-05 2010-02-02 Thomsen Joern Oddershede Supplement preparation
AU2004260578B2 (en) * 2003-08-05 2010-07-29 Jorn Oddershede Thomsen Supplement preparation
WO2013163324A1 (fr) * 2012-04-26 2013-10-31 Balaguer Xavier Gras Méthode de traitement du prurit avec de l'extrait de cartilage

Also Published As

Publication number Publication date
AUPO920597A0 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
US9220290B2 (en) Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US5888984A (en) Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US20130052271A1 (en) Compositions and Methods for Treating Pain
US11058735B2 (en) Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract
US20070098671A1 (en) Composition and method of treatment for irritated skin
JP2001504463A (ja) ククイノキナッツ油を含有する医薬組成物
WO2013103944A1 (fr) Compositions et méthodes de traitement d'affections cutanées
US20120034320A1 (en) Skin Penetration Composition
WO2002038123A1 (fr) Composition pour la peau
US20200345787A1 (en) Camel hump-oil based herbal compositions and method of making the same
ES2249008T3 (es) Composiciones para el tratamiento del acne.
US20030125303A1 (en) Transdermal formulation for repair and maintenance of connective tissue
EP1180940A2 (fr) Substance active et combinaison de substances actives pour l'homme et les animaux
WO1999013891A1 (fr) Preparation therapeutique renfermant du cartilage de requin
EP2310022A1 (fr) Médicament topique
US20040146587A1 (en) Topical composition for relief of pain and minor skin irritations
JPH10175868A (ja) 津液改善組成物
RU2469704C1 (ru) Сыворотка "регенерин" для наружного применения с противовоспалительным и регенерирующим эффектом
JP6943941B2 (ja) レモンバーム抽出物を有効成分として含む注射剤及び化粧料組成物
Mansour et al. A botanical nano ozonated erotic oil composition with maximum bioavailability for men
WO2016081724A2 (fr) Procédé pour la prévention et le traitement de l'acné
WO2023014640A1 (fr) Méthodes et composés pour la réparation et la cicatrisation intensives de la peau par un traitement biologique naturel
Mansour et al. A botanical nano ozonated composition with maximum bioavailability for burns
RU2053783C1 (ru) Средство для лечения ран, язв, ожогов
BR102019009943A2 (pt) formulação cosmética para cuidados da saúde dos pés e uso da mesma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WA Withdrawal of international application
NENP Non-entry into the national phase

Ref country code: CA